Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mega Genomics Limited ( (HK:6667) ) has shared an announcement.
Mega Genomics Limited has announced a delay in the publication of its 2025 interim results, which is attributed to ongoing issues with the release of its 2024 annual results and report. Consequently, trading of the company’s shares remains suspended on the Hong Kong Stock Exchange since April 1, 2025, with no specified date for resumption. This situation may impact stakeholders’ confidence and requires cautious consideration by investors.
More about Mega Genomics Limited
Mega Genomics Limited is a company incorporated in the Cayman Islands, focusing on genomics and related services. It is listed on the Stock Exchange of Hong Kong and operates within the biotechnology industry.
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.61B
Find detailed analytics on 6667 stock on TipRanks’ Stock Analysis page.